DRKS00000472CompletedPhase 1
Clinical evaluation of the new nicotinic receptor marker (-)- [18F]NCFHEB with Positron Emission Tomography in Alzheimer’s disease patients, and healthy volunteers
niversität Leipzig0 sites49 target enrollmentStarted: August 2, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 49
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomized controlled study
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 55 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Healthy volunteers:
- •1 Males/females aged greater than or equal to 55 years of age, females must be without childbearing potential (confirmed by either: age = 60; or history of hysterectomy; or hormone analysis in serum: Estradiol = 20 pg/mL and follicle stimulating hormone (FSH) = 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start)
- •2 Able to understand the information provided on purpose and conduct of the clinical study
- •3 Have signed the informed consent to participate in the study
- •4 No history of any psychiatric or neurological diseases. Clinical Dementia Rating (CDR) score of 0 (zero) and psychometric test results lying within an interval of one standard deviation from the mean value (mean value and standard deviations adjusted for age and education), for all subtests of the test battery applied.
- •5 Brain MRI: medial temporal lobe atrophy (MTA) score = 2 on the Scheltens scale 54 (scale ranging from 0 to 4)
- •6 Brain MRI: white matter lesion (WML) score = 2 on the Fazekas scale 15 (scale ranging from 0 to 3)
- •7 Adequate visual and auditory acuity to complete neuropsychological testing, as assessed by the recruiting investigator
- •AD patients
- •1 Males/females aged greater than or equal to 55 years of age; females must be without childbearing potential (confirmed by either: age = 60; or history of hysterectomy; or hormone analysis in serum: Estradiol = 20 pg/mL and follicle stimulating hormone FSH = 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start)
- •2 Capable of understanding the information provided on purpose and conduct of the clinical study and able to give meaningful informed consent by himself / herself
- •3 Have signed the informed consent to participate in the study
- •4 Adequate visual and auditory acuity to complete neuropsychological testing, as assessed by the recruiting investigator
- •5 AD patients, characterized by:
- •a) Progressive cognitive decline with DSM-IV criteria for Dementia
- •b) Probable Alzheimer Disease according to the NINCDS-ARDA criteria
- •c) Severity of dementia: mild, with a score of 1 on the Clinical Dementia Rating (CDR) and 18-26 on the Mini Mental State Examination (MMSE)
Exclusion Criteria
- •Healthy volunteers
- •1 Clinical significant abnormal physical examination
- •2 Evidence of any significant psychiatric or neurological illness from history, clinical or para – clinical findings
- •3 History, physical or imaging findings of any significant neurological illness such as cerebrovascular disease, inflammatory or infectious disease and other neurodegenerative diseases
- •4 Grossly pathological findings in brain MRI
- •AD patients
- •1 History, physical or imaging findings of other neurological illness apart from AD such as cerebrovascular disease, inflammatory or infectious disease and other degenerative diseases or other dementia types such as fronto-temporal lobe dementia or Lewy body disease.
- •2 Use of cholinesterase inhibitors.
- •All subjects
- •1 Previous significant occupational exposure to ionizing radiation or in whom, within the last 10 years, radioactive substances were applied for the purposes of research.
- •2 Hematological or biochemical parameters that are outside the normal range and are considered clinically significant by the investigator.
- •3 History of alcohol or drug abuse/dependence
- •4 History of major allergic reactions
- •5 History of epilepsy
- •6 History of electroconvulsive therapy
- •7 Any significant disease or unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection)
- •8 Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the volunteer’s safety
- •9 Participants in whom magnetic resonance imaging (MRI) is contraindicated.
- •10 Patient / Volunteer is in custody by order of an authority or a court of law
- •11 Exclusion periods from other studies or simultaneous participation in other clinical studies
- •12 Patient / Volunteer has received another investigational drug in the preceding 2 months
- •13 Previous enrollment in this study
- •14 Active Smokers
Investigators
Similar Trials
Recruiting
Phase 1
Pilot study of safety and efficacy of nicotinamide (vitamin B3) in OPA1 Dominant Optic Atrophy -NICOPA1-TODominant Optic AtrophyCTIS2023-506214-52-00Centre Hospitalier Universitaire D Angers25
Completed
Not Applicable
Effects of nicotinergic receptor stimulation with vareniclin on focal and non-focal plasticity in schizophrenia patientsF20SchizophreniaDRKS00013735Klinik für Psychiatrie und Psychotherapie- Klinikum der Universität München61
Active, not recruiting
Not Applicable
Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit.For the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit abruptly.MedDRA version: 9.1Level: LLTClassification code 10008374Term: Cessation of smokingMedDRA version: 9.1Level: LLTClassification code 10053325Term: Smoking cessation therapyMedDRA version: 9.1Level: LLTClassification code 10059612Term: Tobacco withdrawal symptomsEUCTR2008-006845-13-DEMcNeil AB (Johnson & Johnson Consumer and Personal Products Worldwide, J&J CPPW)465
Active, not recruiting
Not Applicable
Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit.For the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit abruptly.MedDRA version: 9.1Level: LLTClassification code 10008374Term: Cessation of smokingMedDRA version: 9.1Level: LLTClassification code 10053325Term: Smoking cessation therapyMedDRA version: 9.1Level: LLTClassification code 10059612Term: Tobacco withdrawal symptomsEUCTR2008-006845-13-DKMcNeil AB (Johnson & Johnson Consumer and Personal Products Worldwide, J&J CPPW)465
Not yet recruiting
Phase 4
Comparison of effectiveness of Bupropion and Nicotine gum for smokers dependent on OpioidsCTRI/2024/05/067468ational Drug Dependent Treatment Centre